KYV-102 Market Summary

Key Factors Driving KYV-102 Growth

1. Proven CD19 CAR-T Mechanism in Autoimmune Diseases

KYV-102 is built on the same fully human CD19 CAR-T construct used in KYV-101, which has demonstrated promising activity across multiple autoimmune diseases. CD19-directed CAR-T therapy aims to achieve deep B-cell depletion and an "immune reset," potentially leading to long-term remission after a single treatment. Kyverna has reported encouraging outcomes with KYV-101 in diseases such as stiff person syndrome (SPS), myasthenia gravis (MG), lupus nephritis (LN), rheumatoid arthritis (RA), and multiple sclerosis (MS), providing strong biological validation for KYV-102.

2. Whole-Blood Manufacturing Eliminates Apheresis

A major differentiator for KYV-102 is its proprietary manufacturing process. Traditional autologous CAR-T therapies require leukapheresis, which can be burdensome for autoimmune patients and treatment centers. KYV-102 uses a whole-blood rapid manufacturing approach, eliminating the need for apheresis collection. This could significantly improve patient convenience, broaden treatment eligibility, and reduce logistical complexity. Kyverna specifically highlights this feature as a key strategy to expand CAR-T access in autoimmune diseases.

3. Potential for Faster Manufacturing and Lower Cost of Goods

Kyverna has stated that KYV-102's rapid manufacturing process is designed to reduce turnaround times relative to conventionally manufactured CAR-T products while lowering production costs. Manufacturing efficiency is a critical commercial driver in cell therapy because it can improve margins, enhance scalability, and facilitate broader reimbursement adoption. Reduced manufacturing complexity could provide a meaningful competitive advantage if clinical efficacy remains comparable to KYV-101.

4. Large and Expanding Autoimmune Disease Opportunity

The addressable market extends across numerous severe B-cell-mediated autoimmune diseases, including:

• Generalized myasthenia gravis (gMG)

• Lupus nephritis (LN)

• Systemic lupus erythematosus (SLE)

• Stiff person syndrome (SPS)

• Rheumatoid arthritis (RA)

• Multiple sclerosis (MS)

• Systemic sclerosis

Many of these diseases require lifelong immunosuppressive therapy and remain inadequately controlled in a substantial proportion of patients. The potential for a one-time cellular therapy capable of inducing durable remission represents a transformative treatment paradigm.

KYV-102 Recent Developments

In 2025, Kyverna reported that KYV-101 demonstrated profound reductions in disease-associated autoantibodies and meaningful improvements in disease activity in difficult-to-treat rheumatoid arthritis patients. The company also reported that approximately 100 patients had been treated with KYV-101 across studies, providing an expanding safety and efficacy database that may de-risk KYV-102 development.

 

“KYV-102 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of KYV-102 for potential indication like Autoimmune disorders in the 7MM. A detailed picture of KYV-102’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the KYV-102 for potential indications. The KYV-102 market report provides insights about KYV-102’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current KYV-102 performance, future market assessments inclusive of the KYV-102 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of KYV-102 sales forecasts, along with factors driving its market.

KYV-102 Drug Summary

KYV-102 is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by Kyverna Therapeutics for the treatment of severe autoimmune diseases. The therapy is engineered by collecting a patient’s own T cells and modifying them ex vivo to express a fully human anti-CD19 CAR, enabling targeted depletion of CD19-positive B cells that drive autoantibody production and immune dysregulation. KYV-102 is designed to induce deep B-cell depletion and potentially reset the immune system following a single infusion, offering the possibility of durable, treatment-free remission. The product is being evaluated across multiple autoimmune indications, including progressive multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis, building on the growing clinical evidence supporting CD19-directed CAR T-cell therapy in autoimmune disorders. Early clinical experience has demonstrated robust B-cell depletion, encouraging efficacy signals, and a manageable safety profile, with low rates of severe cytokine release syndrome and neurotoxicity. Through its one-time administration and immune-resetting mechanism, KYV-102 represents a novel cell-based therapeutic approach aimed at transforming the treatment paradigm for refractory autoimmune diseases. The report provides KYV-102’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the KYV-102 Market Report

The report provides insights into:

• A comprehensive product overview including the KYV-102 MoA, description, dosage and administration, research and development activities in potential indication like Autoimmune disorders.

• Elaborated details on KYV-102 regulatory milestones and other development activities have been provided in KYV-102 market report.

• The report also highlights KYV-102‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.

• The KYV-102 market report also covers the patents information, generic entry and impact on cost cut.

• The KYV-102 market report contains current and forecasted KYV-102 sales for potential indications till 2034.

• Comprehensive coverage of the late-stage emerging therapies for respective indications.

• The KYV-102 market report also features the SWOT analysis with analyst views for KYV-102 in potential indications.

Methodology

The KYV-102 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

KYV-102 Analytical Perspective by DelveInsight

• In-depth KYV-102 Market Assessment

This KYV-102 sales market forecast report provides a detailed market assessment of KYV-102 for potential indication like Autoimmune disorders in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted KYV-102 sales data uptil 2034.

• KYV-102 Clinical Assessment

The KYV-102 market report provides the clinical trials information of KYV-102 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

KYV-102 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

KYV-102 Market Potential & Revenue Forecast

• Projected market size for the KYV-102 and its key indications

• Estimated KYV-102 sales potential (KYV-102 peak sales forecasts)

• KYV-102 Pricing strategies and reimbursement landscape

KYV-102 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)

• KYV-102 Market positioning compared to existing treatments

• KYV-102 Strengths & weaknesses relative to competitors

KYV-102 Regulatory & Commercial Milestones

• KYV-102 Key regulatory approvals & expected launch timelines

• Commercial partnerships, licensing deals, and M&A activity

KYV-102 Clinical Differentiation

• KYV-102 Efficacy & safety advantages over existing drugs

• KYV-102 Unique selling points

 

KYV-102 Market Report Highlights

• In the coming years, the KYV-102 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.

• The KYV-102 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KYV-102’s dominance.

• Other emerging products for Autoimmune disorders are expected to give tough market competition to KYV-102 and launch of late-stage emerging therapies in the near future will significantly impact the market.

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KYV-102 in potential indications.

• Analyse KYV-102 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.

• Our in-depth analysis of the forecasted KYV-102 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of KYV-102 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of KYV-102? How strong is KYV-102’s clinical and commercial performance?

• What is KYV-102’s clinical trial status in each individual indications such as Autoimmune disorders and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KYV-102 Manufacturers?

• What are the key designations that have been granted to KYV-102 for potential indications? How are they going to impact KYV-102’s penetration in various geographies?

• What is the current and forecasted KYV-102 market scenario for potential indications? What are the key assumptions behind the forecast?

• What are the current and forecasted sales of KYV-102 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?

• What are the other emerging products available and how are these giving competition to KYV-102 for potential indications?

• Which are the late-stage emerging therapies under development for the treatment of potential indications?

• How cost-effective is KYV-102? What is the duration of therapy and what are the geographical variations in cost per patient?